Blood sugar tracking is officially general-wellness territory. Abbott announced Thursday that its prescription-free continuous glucose monitor, Lingo, is now available for sale in the US. It’s been cleared by the US Food and Drug Administration for adults who don’t use insulin and would like insights into how their diet and daily life affects blood sugar.
Lingo pricing starts at $49 for a two-week sensor and goes up based on length of plan. You can use your FSA or HSA dollars to purchase it. Lingo has already been available in the UK.
Last month, Dexcom, another diabetes tech company, announced that its over-the-counter continuous glucose monitor called Stelo is available for purchase. Stelo was cleared by the FDA for people with diabetes who don’t need insulin and any other adult who wants more insight into how the foods they eat impacts their glucose levels. It costs $99 for a two-pack of sensors, which is a month’s supply. Like for Lingo, you can use your FSA and HSA dollars to purchase it.
While people with diabetes need to monitor blood sugar levels to ensure their body has the appropriate amount to stay safe, blood sugar is everybody’s primary form of energy. How well the body uses blood sugar is also a measure of metabolic health — a term the medical community is still working out that describes how the body uses energy and how at-risk someone may be for health problems like heart disease.
But accurately tracking blood sugar, or even putting a firm finger on what it means to be “metabolically healthy,” is tricky. What we eat, the type of exercise we recently did and even the stress we’re under stress can all impact glucose levels. And consumer wearables like smartwatches and smart rings can’t measure blood glucose, despite the existence of some counterfeit devices on the market that haven’t been FDA cleared.
This means the world of blood sugar has been the domain of diabetes tech companies like Dexom and Abbott, which already have sensors and technology — continuous glucose monitors — many people with diabetes use every day. And the companies leading diabetes tech have also been laying down the framework to make metabolic health more mainstream. Both of Abbott’s over-the-counter CGMS are based on its popular FreeStyle Libre sensor technology, as Dexcom’s prescription-free Stelo follows the popular G6 and G7 CGM technology for people who use insulin.
Here’s what we know about the new over-the-counter CGMs, as well as insight from a company working on a new, non-invasive way to measure blood sugar.
Read more: The FDA Wants to Remind You That Your Smartwatch Can’t Measure Blood Sugar Yet
The Stelo by Dexcom is a continuous glucose monitor for people with diabetes who don’t need insulin, opening up the biosensor market to people with Type 2 diabetes.
Over-the-counter CGMs are officially here. Who actually needs one?
Dexcom’s Stelo is available now. It was designed for people with Type 2 diabetes and prediabetes in mind, so they can see how different foods, sleeping habits, stressful events and more impact glucose levels. It’s also been cleared by the FDA for any adult who wants to “better understand how diet and exercise may impact blood sugar levels.”
Abbott’s Lingo, which it first announced at CES in 2022 along with plans for a whole line of biosensors that track more than glucose, is also available for purchase. The FDA cleared another glucose monitor from Abbott made specifically for people with Type 2 diabetes earlier this summer, though it’s not currently available.
CGMs are worn on the back of your arm like and resemble a small bandage. When attached, a tiny sensor that goes slightly below your skin reads blood glucose information and sends it to a paired app, allowing you to track your blood sugar information throughout the day and make note of any trends. Some CGMs have already been used for “biohacking” glucose levels by people who want to know how their body responds to food or what impacts their glucose levels. Companies such as Nutrisense are marketed more as a consumer device, but they require a prescription, which is taken care of through their websites.
However, the question of “who actually needs these?” remains. As Dr.Robert H. Shmerling wrote in an article for Harvard Health Publishing, CGMs can cost several thousand dollars a year, and companies marketing their use for the general public stand to make a big profit in an area of health that, as of now, does not have the research supporting it outside diabetes management. In its press release, Abbott pointed to research finding that just 12% of American adults are considered “metabolically healthy,” but glucose measurements are just one of a few factors used to qualify metabolic health.
On the other hand, one in three Americans have prediabetes — a step before Type 2 diabetes which can be reversible. Providing actionable information on higher-than-average blood sugar trends could provide many people with the information needed to make choices for their health — if they can afford it, that is. Neither Dexcom nor Abbott have provided exact prices for their consumer CGMs at this time, but costs for CGMs for people with diabetes who do not have health insurance remains a barrier to health care access.
Because consumer CGMs don’t require a prescription and many cases likely wouldn’t be considered medically necessary, someone who may have a higher risk of developing Type 2 diabetes would still likely pay top dollar for an over-the-counter CGM. The high cost of biosensors is one reason there’s interest in non-invasive, even more consumer-friendly measures of tracking blood sugar.
Read more: An AI-Built ‘Digital Twin’ Could Improve Your Health, This Startup Says
At CES 2022, Abbott announced a new line of consumer biowearables called Lingo for people who don’t have diabetes and don’t need a prescription. They launched first in the UK and are expected to hit the US market this summer.
Non-invasive blood sugar monitoring makes an appearance at the American Diabetes Association conference
There’s no way to accurately measure blood sugar levels without getting at least a little bit under someone’s skin. Even CGMs require a tiny sensor on the wearable patch, even though it’s arguably less invasive than a finger prick.
One company, Know Labs, is working to change that. The company was at the American Diabetes Association Scientific Sessions in Orlando earlier this summer and presented promising results on the ability of its wearable device, the KnowU, to get stable readings of blood sugar without penetrating the skin. The company is still a ways out from having a device ready for the market and it’s still collecting data to send to the FDA — the prototype is still bulkier than a CGM, potentially making it a harder sell even if it’s less invasive. But the company is expanding on the idea and use of photonics and sensors already integrated (for different purposes) into smartwatches and used to measure factors like blood oxygen.
Because LEDs can’t accurately track glucose information, Know Labs had to go “further out on the electromagnetic spectrum,” the company’s CEO Ron Erickson told CNET. He said that, while a medical-grade device is likely the first step for the company, he’s not opposed to opening up the patented technology to consumer wearable devices.
Calling Know Labs’ technology “form-factor agnostic,” Erickson wants glucose tracking to feed health trends — which is the whole point of consumer wearables that give you health trends.
“My longer vision, beyond glucose, is predictive health,” he said.
